AbbVie welcomes you to lecture on AML at Skejby & live streaming:

Evolving treatment options for patients with AML ineligible for intensive chemotherapy

WHEN: Tuesday, October 29th from 16.00-18.00

WHERE: Aarhus University Hospital **AUH SYD, auditorium C114-101. Indgang C, C110** or join online

A light meal and refreshments will be served after the meeting.

PROGRAM

16.00 – 16.10 **Welcome**
Dr. Daniel Tuyet Kristensen

16.10 – 17.00 **Lecture: Evolving treatment options for patients with AML ineligible for intensive chemotherapy**
Prof. Dr. Christoph Röllig

17.00-18.00 **Clinical cases / Q&A session**
Dr. Daniel Tuyet Kristensen & Prof. Dr. Christoph Röllig

Please send your registration for the meeting before October 16th to Daniel Tuyet Kristensen:

dankrt@rm.dk

Please note if you will participate in person or online, to receive a link.

Lecturer:

PROF. DR. CHRISTOPH RÖLLIG, MD MSC
Consultant Hematologist, Head of Clinical Trial Unit,
Secretary of SAL Study Group, Universitätsklinikum Dresden.

Christoph Röllig works as consultant haematologist at the University Hospital Dresden, Germany. Christoph Röllig has more than 20 years of clinical experience in hematology, and has published and co-authored more than 150 articles on AML and MultipleMyeloma. He is the coordinating investigator of several Investigator Initiated Trials in AML and the principal investigator in more than 50 clinical trials in AML. He is the first author of German AML guidelines and co-author of the ELN 2022 guidelines on diagnosis and management of AML.Prof. Röllig is coordinating the German Study Alliance Leukemia Study group (SAL), he is a member of Working Group for Clinical Trials at the German Society for Hematology and Oncology (DGHO), member of the Scientific Working Group for AML at the European Haematology Association (EHA) and chairs the AML Working Group of the European LeukemiaNet (ELN).

DK-VNCAML-240014 v 1.0 Juli 2024

AbbVie A/S, Titangade 11 2200 København N www.abbvie.dk

abbvie